{"schema_version":"1.0","type":"article","title":"藥證到手，錢就到帳？從台新藥、智擎看懂授權金怎麼變成現金","url":"https://drugnews.com.tw/articles/2026-09-29-biotech-milestone-payments-formosa-pharmaengine.html","markdown_url":"https://drugnews.com.tw/articles/2026-09-29-biotech-milestone-payments-formosa-pharmaengine.md","lang":"zh-Hant","date":"2026-09-29","publish_at":"2026-09-29T08:00:00+08:00","updated_at":"2026-09-29","category":"商業分析系列","topic":"商業分析系列","tags":["新藥授權","里程碑付款","台新藥","智擎","Genmab","現金流","BD交易"],"summary":"藥證、付款事件與實際收款之間，有哪些條件？以Genmab歷史里程碑、台新藥的股票結算與毛利合作，以及智擎2026上半年財報，解析新藥授權生意如何從進展走向可運用資源。","key_points":[],"facts":[],"sections":["參考來源"],"references":[{"title":"[1] [Eyenovia 2024 Form 10-K]","source":"","date":"","url":"https://www.sec.gov/Archives/edgar/data/1682639/000141057825000743/eyen-20241231x10k.htm"},{"title":"[2] [Hyperion DeFi／原Eyenovia 2025Q2 Form 10-Q]","source":"","date":"","url":"https://www.sec.gov/Archives/edgar/data/1682639/000141057825001740/hypd-20250630x10q.htm"},{"title":"[3] [Harrow Form 8-K（2025-06-09）]","source":"","date":"","url":"https://www.sec.gov/Archives/edgar/data/1360214/000164117225014234/form8-k.htm"},{"title":"[4] [Harrow／台新藥共同公告]","source":"","date":"","url":"https://www.sec.gov/Archives/edgar/data/1360214/000164117225014234/ex99.htm"},{"title":"[5] [智擎：將收到US$50m公告（2025-02-05）]","source":"","date":"","url":"https://www.pharmaengine.com/en/investors/investors_5/88"},{"title":"[6] [智擎ONIVYDE產品與里程碑頁]","source":"","date":"","url":"https://www.pharmaengine.com/en/product/index/8"},{"title":"[7] [智擎2026年第二季財報，第20頁]","source":"","date":"","url":"https://www.pharmaengine.com/en/uploads/en/investors_3/20260817374.pdf"},{"title":"[8] [Genmab：DARZALEX銷售里程碑（2017-01-06）]","source":"","date":"","url":"https://www.globenewswire.com/news-release/2017/01/06/904135/0/en/Genmab-Achieves-USD-25-Million-Sales-Milestone-in-DARZALEX-daratumumab-Collaboration-with-Janssen.html"},{"title":"[9] [Genmab：日本首次商業銷售里程碑（2017-11-14）]","source":"","date":"","url":"https://www.globenewswire.com/news-release/2017/11/14/1186131/0/en/Genmab-Achieves-USD-25-Million-Milestone-for-First-Commercial-Sale-of-DARZALEX-daratumumab-in-Japan-and-Updates-Financial-Guidance.html"},{"title":"[10] [Genmab／Janssen授權合約（2012-08-30），SEC公開附件]","source":"","date":"","url":"https://www.sec.gov/Archives/edgar/data/1434265/000104746919003334/a2238822zex-10_1.htm"},{"title":"[11] [台新藥官網：Harrow接手公告（2025-06-09）]","source":"","date":"","url":"https://www.formosapharma.com/harrow-acquires-u-s-commercial-rights-to-byqlovi-clobetasol-propionate-ophthalmic-nanosuspension-0-05-from-formosa-pharmaceuticals/"},{"title":"[12] [台新藥2026Q1財報英文版，第34頁]","source":"","date":"","url":"https://www.formosapharma.com/wp-content/uploads/2026/06/%E5%8F%B0%E6%96%B0%E8%97%A5.2026%E5%90%88%E4%BD%B5%E7%AC%AC%E4%B8%80%E5%AD%A3.FS_.AllReport.ENG_0529.pdf"}],"images":[{"alt":"三階段流程：事件達成、通知與請款、實際收款；左側列出依合約擇定的可能觸發事件。","url":"https://drugnews.com.tw/assets/articles/biotech-milestone-payments-formosa-pharmaengine/01_%E4%BA%8B%E4%BB%B6%E8%AB%8B%E6%AC%BE%E6%94%B6%E7%8F%BE_ZH_v2.png"},{"alt":"以授權合約為中心，四角呈現責任、事件、證據與權利承接。","url":"https://drugnews.com.tw/assets/articles/biotech-milestone-payments-formosa-pharmaengine/02_%E5%90%88%E7%B4%84%E6%8E%A7%E5%88%B6%E6%AC%8A_ZH_v1.png"},{"alt":"年度銷售達5億美元與日本首次商業銷售分別觸發2,500萬美元。","url":"https://drugnews.com.tw/assets/articles/biotech-milestone-payments-formosa-pharmaengine/03_%E6%AD%B7%E5%8F%B2%E8%A7%B8%E7%99%BC%E5%B0%8D%E7%85%A7_ZH_v1.png"},{"alt":"左右兩種收入及收款狀態，490為979.5子集；截至2026年6月30日。","url":"https://drugnews.com.tw/assets/articles/biotech-milestone-payments-formosa-pharmaengine/04_%E8%AA%8D%E5%88%97%E8%88%87%E6%94%B6%E6%AC%BE_ZH_v1.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/biotech-milestone-payments-formosa-pharmaengine/01_%E4%BA%8B%E4%BB%B6%E8%AB%8B%E6%AC%BE%E6%94%B6%E7%8F%BE_ZH_v2.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-09-29）。藥證到手，錢就到帳？從台新藥、智擎看懂授權金怎麼變成現金。https://drugnews.com.tw/articles/2026-09-29-biotech-milestone-payments-formosa-pharmaengine.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-09-29-biotech-milestone-payments-formosa-pharmaengine-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}